Webinars
NT-proBNP- scientific and clinical relevance
NT-proBNP, N-terminal pro-B-type natriuretic peptide, is released from the heart, specifically from the cardiac ventricles, in response to increased pressure and stretching of heart muscle cells.
NT-proBNP levels rise in conditions where the heart is under stress or strain, such as heart failure. Therefore, it's often used as a diagnostic marker for heart failure, helping doctors assess the severity of the condition, determine prognosis, and guide treatment decision.
It's important to note that while NT-proBNP levels can provide valuable information, they are just one piece of the diagnostic puzzle, and clinical judgment should always be used alongside laboratory results for accurate diagnosis and management of heart conditions.
Tuberculosis is present in all countries in the world, but it is curable and preventable.
In 2021, an estimated 10.6 million people fell ill with TB worldwide, being the second leading infectious killer after Covid-19, killing 1.6 million people in 2021. US$ 13 billion is needed annually for TB prevention, diagnosis, treatment and care to achieve the global target agreed upon at the 2018 UN high level-meeting on TB. Monitoring TB patients is crucial for ensuring successful treatment outcomes and for preventing the spread of the disease. It allows healthcare providers to assess treatment response, make informed decisions, and prevent treatment failure or relapse . Traditional monitoring methods, such as sputum smear microscopy, which is widely used, and mycobacterial culture, have limitations in terms of time, accuracy, and sensitivity. To address these challenges, the PATHFAST™ TB LAM Ag test offers a revolutionary solution for transforming TB monitoring.
Join our expert in Tuberculosis, Dr. Yassir Shuaib, in this event where he will be discussing about key facts about tuberculosis, scientific background, clinical trial data using PATHFAST TB LAM and clinical applications of the PATHFAST TB LAM.
"Presepsin as a diagnostic tool for sepsis in preterm infants"
Meanwhile, presepsin represents an indispensable biomarker in the neonatal field in Italy, being used in almost every Neonatal Intensive Care Unit (NICU) in Italy. Neonatal sepsis represents a major cause of morbidity and mortality in neonates. Given its high mortality rate if not recognized and treated adequately, a rapid start of adequate antibiotic and supportive therapy is critical to significantly improve patient prognosis. Therefore, presepsin is a new useful marker for early diagnosis of sepsis, even in a pediatric emergency setting. During our webinar, Prof Dani will present data on the applied reference ranges in the neonatal setting as well as studies on the accuracy of presepsin as a biomarker in early onset sepsis (EOS) and late onset sepsis (LOS).
"Cardiac troponin in suspected myocardial infarction"
Dr. Neumann from the UKE in Hamburg will contribute an interesting scientific webinar on the topic of troponin diagnostics. The UKE in Hamburg evaluated PATHFAST™ for the 0/1 hour algorithm in the past which led to the listing of PATHFAST™ in the ESC Guidelines. In this webinar, Dr. Neumann shares his experience with PATHFAST™ and discusses other exciting topics such as the relevance of acute myocardial infarction (AMI) today, the role of high-sensitivity troponin today, and new diagnostic concepts. Learn about Emergency biomarkers, Workflow and clinical algorithms in the ED and the Advantages of using biomarkers.
“How to improve clinical practice using sepsis biomarkers”
Prof. Evangelos J. Giamarellos-Bourboulis . Sepsis diagnosis and prognosis is still a big challenge for laboratory medicine. In this webinar Prof. Evangelos J. Giamarellos-Bourboulis, will discuss about the use of sepsis biomarkers and how they can improve our clinical practice.
"Optimal use of hsTnI in the ED: advantages and barriers”
Prof. John Parissis from University Clinic of Emergency Medicine in Athens, Greece . Measurement of cardiac troponin is an important component for the rapid and appropriate diagnosis of AMI patients in the often very frequented emergency departments. Learn about the contemporary use of troponin, the common algorithms, the advantages but also the limitations of troponin diagnostics in the emergency department.
“How to improve clinical practice using sepsis biomarkers”
Prof. Evangelos J. Giamarellos-Bourboulis . Sepsis diagnosis and prognosis is still a big challenge for laboratory medicine. In this webinar Prof. Evangelos J. Giamarellos-Bourboulis, will discuss about the use of sepsis biomarkers and how they can improve our clinical practice.
"PCT and Presepsin, opponents or complementary biomarkers in laboratory medicine practice?"
Prof. Plebani. Within the frame of this presentation Prof. Plebani will give a recent overview of the current clinical application of presepsin and PCT and show latest studies, discussing the common biomarker approach in routine clinical diagnostics from a scientific perspective.